LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

Search

Twist Bioscience Corp

Abrir

SetorSaúde

46.92 8.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

43.84

Máximo

46.85

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+19.02% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

127M

2.7B

Abertura anterior

38.06

Fecho anterior

46.92

Sentimento de Notícias

By Acuity

50%

50%

169 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de mar. de 2026, 23:15 UTC

Notícias Principais

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 de mar. de 2026, 22:36 UTC

Notícias Principais

Australian Government Rules Out Boots on the Ground in the Middle East

30 de mar. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 de mar. de 2026, 21:00 UTC

Ganhos

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 de mar. de 2026, 20:15 UTC

Notícias Principais

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 de mar. de 2026, 23:36 UTC

Conversa de Mercado

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 de mar. de 2026, 22:49 UTC

Conversa de Mercado

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 de mar. de 2026, 22:44 UTC

Conversa de Mercado

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 de mar. de 2026, 22:43 UTC

Conversa de Mercado

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 de mar. de 2026, 22:42 UTC

Conversa de Mercado

South32 Should Go for Growth, Says New Bull -- Market Talk

30 de mar. de 2026, 22:18 UTC

Conversa de Mercado

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 de mar. de 2026, 22:05 UTC

Conversa de Mercado

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 de mar. de 2026, 21:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 de mar. de 2026, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 de mar. de 2026, 21:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

30 de mar. de 2026, 20:09 UTC

Ganhos

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 de mar. de 2026, 20:00 UTC

Notícias Principais

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

19.02% parte superior

Previsão para 12 meses

Média 53 USD  19.02%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

169 / 349 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat